Neurocrine Biosciences
$11.19 B
Share price
Change (1 day)
Change (1 year)
Neurocrine Biosciences is an American biopharmaceutical company that develops treatments for neurological and endocrine-related diseases and disorders.

Neurocrine Biosciences (NBIX) Fails to deliver data

Key failure to deliver metrics for Neurocrine Biosciences :

A Failure to deliver also known as fails-to-deliver or FTD occurs when a buyer or seller is unable to meet his trading obligations. FTDs for US listed companies are reported to the SEC and published twice a month. Therefore there is a certain delay between the reporting and the publishing of the data.

Failures to deliver for Neurocrine Biosciences (NBIX) - 3 month history

Number of shares, 3 month chart

Biweekly Failures to deliver volume for Neurocrine Biosciences (NBIX) - since 2013

Volume in USD (price x number of shares), data since 2013

Neurocrine Biosciences (NBIX) Failure to deliver volume, Year over Year

Year Volume (Price x Shares) Change
2023$15.28 M-52.74%
2022$32.34 M-26.75%
2021$44.16 M193.08%
2020$15.06 M-65.24%
2019$43.34 M-3.16%
2018$44.76 M-18.56%
2017$54.96 M78.43%
2016$30.8 M53.41%
2015$20.07 M66.9%
2014$12.03 M241.08%
2013$3.52 M

FTD volume in the last 3 months for similar companies or competitors

Company FTD volume (3months) FTD volume (1 year) Country
$39.54 M$0.40 B๐Ÿ‡บ๐Ÿ‡ธ USA
$36.71 M$0.40 B๐Ÿ‡บ๐Ÿ‡ธ USA
$20.9 M$0.18 B๐Ÿ‡บ๐Ÿ‡ธ USA
$60.89 M$0.13 B๐Ÿ‡บ๐Ÿ‡ธ USA
$0.03 M$4.12 M๐Ÿ‡บ๐Ÿ‡ธ USA
$0.47 M$1.52 M๐Ÿ‡บ๐Ÿ‡ธ USA
$0.05 M$0.05 M๐Ÿ‡บ๐Ÿ‡ธ USA
$7.94 M$44.25 M๐Ÿ‡ฌ๐Ÿ‡ง UK